New Prescription Option for Fibromyalgia Treatment

New Prescription Option for Fibromyalgia Treatment

SKU: CEI-NEW-PRESCRIP-1765238400-PODCAS-PH-9643
2400.00 USD In stock Buy at Merchant

This course covers the newly approved sublingual cyclobenzaprine HCl for fibromyalgia, including its mechanism of action, clinical trial outcomes, dosing, and pharmacist responsibilities.

  • The description claims the product is a new therapeutic option for fibromyalgia.
Specifications
Duration
30m
CEUs
0.05
Target Role
Pharmacist

AI Readiness

Good foundation, but some important product data is still missing.

75%
3 important fields missing Claim to view full AI report
Data sourced from www.ceimpact.com. Last updated: The description was auto-generated by an AI model based on the merchant's description. It may not be accurate or complete.
Claim www.ceimpact.com to see AI Product Health

Takes ~2 minutes. No storefront changes.